GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Olema Pharmaceuticals inc (NAS:OLMA) » Definitions » ROC (Joel Greenblatt) %

Olema Pharmaceuticals (Olema Pharmaceuticals) ROC (Joel Greenblatt) % : -3,540.35% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Olema Pharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Olema Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3,540.35%.

The historical rank and industry rank for Olema Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

OLMA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -42510.89   Med: -5662.11   Max: -2460.91
Current: -2971.88

During the past 6 years, Olema Pharmaceuticals's highest ROC (Joel Greenblatt) % was -2460.91%. The lowest was -42510.89%. And the median was -5662.11%.

OLMA's ROC (Joel Greenblatt) % is ranked worse than
80.68% of 1470 companies
in the Biotechnology industry
Industry Median: -339.53 vs OLMA: -2971.88

Olema Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 32.30% per year.


Olema Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for Olema Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olema Pharmaceuticals ROC (Joel Greenblatt) % Chart

Olema Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -16,600.00 -42,510.89 -2,981.90 -2,460.91 -2,901.88

Olema Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,674.10 -3,126.28 -2,537.19 -2,736.06 -3,540.35

Competitive Comparison of Olema Pharmaceuticals's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Olema Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Olema Pharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Olema Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Olema Pharmaceuticals's ROC (Joel Greenblatt) % falls into.



Olema Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.367) - (12.193 + 0 + 2.849)
=-10.675

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.033) - (15.168 + 0 + 5.465)
=-16.6

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Olema Pharmaceuticals for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-121.664/( ( (3.614 + max(-10.675, 0)) + (3.259 + max(-16.6, 0)) )/ 2 )
=-121.664/( ( 3.614 + 3.259 )/ 2 )
=-121.664/3.4365
=-3,540.35 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Olema Pharmaceuticals  (NAS:OLMA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Olema Pharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Olema Pharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Olema Pharmaceuticals (Olema Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
512, 2nd Street, 4th Floor, San Francisco, CA, USA, 94107
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
Executives
Cyrus Harmon director, officer: Chief Technology Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Paradigm Biocapital Advisors Lp 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10017
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kovacs Shane William Charles officer: Ch. Operating & Financial Off. PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Naseem Zojwalla officer: Chief Medical Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Sean Bohen director, officer: President and CEO C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
David C. Myles officer: Chief Development Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Senai Asefaw 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Paradigm Biocapital International Fund Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Biotechnology Value Fund L P 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Paradigm Biocapital Advisors Gp Llc 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Kinney Horn officer: Chief Business Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Yi Larson director C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116